MOv18 IgE clinical trials

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

This study is testing a new medicine called MOv18 IgE for women with advanced ovarian, endometrial, or triple-negative breast cancer. It aims to find a safe dose and see how well it works, especially in cancers that have a specific marker called Folate Receptor Alpha.